Side by side
Compare companies
Line up to six companies across valuation, growth, profitability, leverage, ownership and technicals. Best and worst per row are highlighted.
| Metric | ANTHEM | ADVENZYMES | CCME | VIVOBIOT | SHREEGANES |
|---|---|---|---|---|---|
| Size & Price | |||||
| Market capitalisation | ₹48,213 Cr | ₹3,072 Cr | ₹54 Cr | ₹38 Cr | ₹19 Cr |
| Enterprise value | ₹48,264 Cr | ₹3,092 Cr | ₹54 Cr | ₹92 Cr | ₹19 Cr |
| Revenue (TTM) | ₹2,002 Cr | ₹750 Cr | ₹0 Cr | ₹47 Cr | ₹23 Cr |
| EBITDA (TTM) | ₹793 Cr | ₹224 Cr | ₹0 Cr | ₹21 Cr | ₹-1 Cr |
| PAT (TTM) | ₹576 Cr | ₹166 Cr | ₹4 Cr | ₹7 Cr | ₹0 Cr |
| Current price | ₹854.05 | ₹274.40 | ₹41.51 | ₹17.26 | ₹0.47 |
| 1-day change | -0.38% | -2.26% | -4.99% | +1.59% | 0% |
| Avg volume (30d) | — | — | — | — | — |
| 52-week high | — | — | — | — | — |
| 52-week low | — | — | — | — | — |
| Distance from 52w high | — | — | — | — | — |
| Distance from 52w low | — | — | — | — | — |
| Valuation | |||||
| Price to earnings | 83.7× | 18.5× | 15.4× | 5.2× | 48.4× |
| Price to book | 15.8× | 1.9× | 1.3× | 0.5× | 0.3× |
| Price to sales | 24.1× | 4.1× | — | 0.8× | 0.8× |
| EV / EBITDA | 60.9× | 13.8× | — | 4.5× | -17.8× |
| Dividend yield | 0.23% | 0.49% | 0% | 0% | 0% |
| Earnings yield | 1.19% | 5.4% | 6.49% | 19.14% | 2.07% |
| PEG ratio | — | 1.1 | — | 0.11 | — |
| Book value / share | ₹54.2 | ₹145.8 | ₹30.8 | ₹35.1 | ₹1.6 |
| EPS (TTM) | ₹10.3 | ₹14.8 | ₹2.7 | ₹3.3 | ₹0.0 |
| Growth | |||||
| Sales growth (1y) | — | 17.1% | — | 2.7% | -78.4% |
| Sales growth (3y CAGR) | — | 11.3% | — | -3.2% | -57% |
| Sales growth (5y CAGR) | — | 8.2% | — | — | -22% |
| Profit growth (1y) | — | 28.7% | — | 187.7% | 35.7% |
| Profit growth (3y CAGR) | — | 16.9% | — | 49% | -42.9% |
| Profit growth (5y CAGR) | — | 2.9% | — | — | 3.5% |
| Qtr sales growth (YoY) | -22.6% | 2.1% | — | — | -20.5% |
| Qtr profit growth (YoY) | -11.7% | -4.6% | — | — | -273.9% |
| Profitability | |||||
| Operating margin | 39.3% | 30.7% | — | 44% | -19.3% |
| Net margin | 27.9% | 23.3% | — | 15.6% | 7.7% |
| Return on equity | 19.5% | 11.1% | -2.9% | 11% | 0.6% |
| Return on capital employed | 27.6% | 13.7% | -2.9% | 15.2% | 0.8% |
| Return on assets | 17.3% | 9.4% | -1.6% | 5.1% | 0.6% |
| ROE (3y avg) | 19.5% | 10.3% | -2% | 7% | 0.7% |
| ROCE (3y avg) | 27.6% | 13.8% | -2.4% | 13.2% | 0.9% |
| Leverage & Quality | |||||
| Debt to equity | 0.02 | 0.01 | 0 | 0.69 | 0 |
| Interest coverage | 124.2× | 85.1× | — | 2.2× | — |
| Current ratio | 5.54 | 9.78 | 8.65 | 1.51 | 70 |
| Working capital days | 124 | 331 | — | 517 | 846 |
| Ownership | |||||
| Promoter holding | 71.4% | 43.2% | 74.4% | 30.6% | 0% |
| Promoter pledge | 0% | 0% | 0% | 0% | 0% |
| FII holding | 2.6% | 26.7% | 0% | 0% | 1.4% |
| DII holding | 13.5% | 4.8% | 0% | 0% | 0% |
| Public holding | 12.5% | 25.3% | 25.7% | 69.4% | 98.6% |
| Promoter holding change (1y) | -3.27% | 0.16% | 63.02% | -8.44% | 0% |
| Technical | |||||
| 50-day moving average | — | — | — | — | — |
| 200-day moving average | — | — | — | — | — |
| Price vs 50 DMA | — | — | — | — | — |
| Price vs 200 DMA | — | — | — | — | — |
| RSI (14) | — | — | — | — | — |
| Return (1m) | — | — | — | — | — |
| Return (3m) | — | — | — | — | — |
| Return (6m) | — | — | — | — | — |
| Return (1y) | — | — | — | — | — |
| Return (3y CAGR) | — | — | — | — | — |
| Relative strength (1y) | — | — | — | — | — |
| Volatility (1y) | — | — | — | — | — |
| Beta | — | — | — | — | — |
best in row weakest in rowRows without a better/worse direction aren't highlighted.